title: [Inhibition of growth and metastasis of human gastric cancer implanted in nude mice by the angiogenesis inhibitor endostatin].
abstract: OBJECTIVE
  To study the effects of angiogenesis inhibitor endostatin on the growth and metastasis of gastric cancer in vivo.
  
  
  METHODS
  Metastatic model simulating human gastric cancer was established by orthotopic implantation of histologically intact human tumor tissue into gastric wall of nude mice. Endostatin was administered sc at dose of 0 mg/kg, 2.5 mg/kg, 10.0 mg/kg and 20.0 mg/kg every other day for seven weeks. Eight weeks after implantation, the tumor size and inhibition rates and intratumoral microvessel density (MVD) and apoptotic index (AI) and the presence of metastasis are evaluated respectively after the mice were sacrificed.
  
  
  RESULTS
  Compared with the untreated controls, growth of the orthotopically implanted tumor was significantly reduced in size in mice treated with endostatin with an inhibition rate 0, 62.7%, 95.8% and 99.9% at the dosage of 0 mg/kg, 2.5 mg/kg, 10.0 mg/kg, and 20.0 mg/kg, respectively. The MVD was also decreased significantly in the treated mice [(13.7 +/- 3.90) versus (5.73 +/- 2.36), (2.17 +/- 1.28) and (0.66 +/- 0.25)]. The AI was increased significantly in the treated mice [(3.91 +/- 2.58)%, versus (6.76 +/- 5.03)%, (18.92 +/- 6.75)% and (28.57 +/- 10.34)%]. The incidences of peritoneal metastases was also significantly inhibited in the treated mice (87.1% versus 54.5%, 16.7% and 0). The incidences of liver metastases was also significantly inhibited in the treated mice (83.9% versus 27.3%, 8.3% and 0). The growth and metastasis of human gastric cancer implanted in nude mice were significantly inhibited in a dose-dependent manner (P < 0.05).
  
  
  CONCLUSIONS
  Angiogenesis inhibitor endostatin can induce apoptosis in gastric cancer by inhibiting tumor angiogenesis and has strong inhibitory effect both on tumor growth and metastasis of human gastric cancer implanted in nude mice.
authors.affiliation: Department of General Surgery, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.
authors.forename: Guofeng
authors.initials: G
authors.lastname: Zhang
authors.forename: Yuanhe
authors.initials: Y
authors.lastname: Wang
authors.forename: Ming'ao
authors.initials: M
authors.lastname: Zhang
authors.forename: Qiang
authors.initials: Q
authors.lastname: Wang
authors.forename: Yunbao
authors.initials: Y
authors.lastname: Luo
authors.forename: Ceran
authors.initials: C
authors.lastname: Han
authors.forename: Youguo
authors.initials: Y
authors.lastname: Lu
authors.forename: Yinyang
authors.initials: Y
authors.lastname: Rao
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D003094:Collagen / Q000627:therapeutic use*; D043169:Endostatins; D006801:Humans; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009362:Neoplasm Metastasis / Q000517:prevention & control; D009368:Neoplasm Transplantation; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D010446:Peptide Fragments / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D043169:Endostatins; D010446:Peptide Fragments; D003094:Collagen